A Nonproliferating Parvovirus Vaccine Vector Elicits Sustained, Protective Humoral Immunity following a Single Intravenous or Intranasal Inoculation

Journal of Virology

Volumn 78, Issue 3, 2004, Pages 1101-1108

  Palmer, Gene A ^a   Brogdon, Jennifer L ^a   Constant, Stephanie L ^a,b   Tattersall, Peter ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CD4 ANTIGEN; COAT PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G2A ANTIBODY; OUTER SURFACE PROTEIN A; PARVOVIRUS VACCINE; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BORRELIA BURGDORFERI; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INTERFERON PRODUCTION; LIFE CYCLE; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; SPIROCHETE; VACCINATION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, SURFACE; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BORRELIA BURGDORFERI; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; GENETIC VECTORS; HUMANS; IMMUNOLOGIC MEMORY; INJECTIONS, INTRAVENOUS; LIPOPROTEINS; LYME DISEASE; LYME DISEASE VACCINES; MICE; MINUTE VIRUS OF MICE; PARVOVIRUS; RECOMBINATION, GENETIC;

EID: 0347003608     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.3.1101-1108.2004     Document Type: Article

References (60)

1. Alexopoulou, L., V. Thomas, M. Schnare, Y. Lobet, J. Anguita, R. T. Schoen, R. Medzhitov, E. Fikrig, and R. A. Flavell. 2002. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat. Med. 8:878-884.
2. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A. Candido, N. L. Kozyr, P. L. Earl, J. M. Smith, H. L. Ma, B. D. Grimm, M. L. Hulsey, H. M. McClure, J. M. McNicholl, B. Moss, and H. L. Robinson. 2002. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 20:1949-1955.
3. Armstrong, A. L., S. W. Barthold, D. H. Persing, and D. S. Beck. 1992. Carditis in Lyme disease susceptible and resistant strains of laboratory mice infected with Borrelia burgdorferi. Am. J. Trop. Med. Hyg. 47:249-258.
4. Arulanandam, B. P., J. M. Lynch, and D. W. Metzger. 2001. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect. Immun. 69:6718-6724.
5. Barbour, A. G. 1984. Isolation and cultivation of Lyme disease spirochetes. Yale J. Biol. Med. 57:521-525.
6. Barthold, S. W., D. S. Beck, G. M. Hansen, G. A. Terwilliger, and K. D. Moody. 1990. Lyme borreliosis in selected strains and ages of laboratory mice. J. Infect. Dis. 162:133-138.
7. Barthold, S. W., M. S. de Souza, J. L. Janotka, A. L. Smith, and D. H. Persing. 1993. Chronic Lyme borreliosis in the laboratory mouse. Am. J. Pathol. 143:959-971.
8. Barthold, S. W., D. H. Persing, A. L. Armstrong, and R. A. Peeples. 1991. Kinetics of Borrelia burgdorferi dissemination and evolution of disease after intradermal inoculation of mice. Am. J. Pathol. 139:263-273.
9. Beenhouwer, D. O., S. Shapiro, M. Feldmesser, A. Casadevall, and M. D. Scharff. 2001. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect. Immun. 69:6445-6455.
10. Brennan, F. R., T. D. Jones, L. B. Gilleland, T. Bellaby, F. Xu, P. C. North, J. Staczek, T. Lin, W. D. Hamilton, and H. E. J. Gilleland. 1999. Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus. Microbiology 145:211-220.
11. Brockstedt, D. G., G. M. Podsakoff, L. Fong, G. Kurtzman, W. Mueller-Ruchholtz, and E. G. Engleman. 1999. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin. Immunol. 92:67-75.
12. Brown, C. S., F. M. DiSumma, J. Rommelaere, A. Y. Dege, J. J. Cornelis, C. Dinsart, and W. J. Spaan. 2002. Production of recombinant H1 parvovirus stocks devoid of replication-competent viruses. Hum. Gene Ther. 13:2135-2145.
13. Brownstein, D. G., A. L. Smith, R. O. Jacoby, E. A. Johnson, G. Hansen, and P. Tattersall. 1991. Pathogenesis of infection with a virulent allotropic variant of minute virus of mice and regulation by host genotype. Lab. Investig. 65:357-364.
14. Bueren, J. A., J. C. Segovia, and J. M. Almendral. 1991. Cytotoxic infection of hematopoietic stem and committed progenitor cells by the parvovirus minute virus of mice. Propagation of an acute myelosuppression in culture. Ann. N. Y. Acad. Sci. 628:262-272.
15. Buning, H., M. U. Ried, L. Perabo, F. M. Gerner, N. A. Huttner, J. Enssle, and M. Hallek. 2003. Receptor targeting of adeno-associated virus vectors. Gene Ther. 10: 1142-1151.
16. Chao, H., and C. E. Walsh. 2001. Induction of tolerance to human factor VIII in mice. Blood 97:3311-3312.
17. Clement, N., T. Velu, and A. Brandenburger. 2002. Construction and production of oncotropic vectors, derived from MVM(p), that share reduced sequence homology with helper plasmids. Cancer Gene Ther. 9:762-770.
18. Coffman, R. L., B. W. Seymour, D. A. Lebman, D. D. Hiraki, J. A. Christiansen, B. Shrader, H. M. Cherwinski, H. F. J. Savelkoul, F. D. Finkelman, M. W. Bond, and T. R. Mosmann. 1988. The role of helper T-cell products in mouse B cell differentiation and isotype regulation, Immunol. Rev. 102: 5-28.
19. Conrad, C. K., S. S. Allen, S. A. Afione, T. C. Reynolds, S. E. Beck, M. Fee-Maki, X. Barrazza-Ortiz, R. Adams, F. B. Askin, B. J. Carter, W. B. Guggino, and T. R. Flotte. 1996. Safety of single-dose administration of an adeno-associated virus (adeno-associated virus)-CFTR vector in the primate lung. Gene Ther. 3:658-668.
20. Constant, S. L., and K. Bottomly. 1997. Induction of Th1 and Th2 CD4+ T-cell responses: the alternative approaches. Annu. Rev. Immunol. 15:297-322.
21. Cotmore, S. F., M. D'Abramo, A., Jr., C. M. Ticknor, and P. Tattersall. 1999. Controlled conformational transitions in the MVM virion expose the VP1 N terminus and viral genome without particle disassembly. Virology 254:169-181.
22. Dupont, F., A. Karim, J. C. Dumon, N. Mine, and B. Avalosse. 2001. A novel MVMp-based vector system specifically designed to reduce the risk of replication-competent virus generation by homologous recombination. Gene Ther. 8:921-929.
23. Dupont, F., L. Tenenbaum, L. P. Guo, P. Spegelaere, M. Zeicher, and J. Rommelaere. 1994. Use of an autonomous parvovirus vector for selective transfer of a foreign gene into transformed human cells of different tissue origins and its expression therein. J. Virol. 68:1397-1406.
24. During, M. J., C. W. Symes, P. A. Lawlor, J. Lin, J. Dunning, H. L. Fitzsimons, D. Poulsen, P. Leone, R. Xu, B. L. Dicker, J. Lipski, and D. Young. 2000. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 287:1453-1460.
25. Flelds, P. A., D. W. Kowalczyk, V. R. Arruda, E. Armstrong, M. L. McCleland, J. N. Hagstrom, K. J. Pasi, H. C. Ertl, R. W. Herzog, and K. A. High. 2000. Role of vector in activation of T-cell subsets in immune responses against the secreted transgene product factor IX. Mol. Ther. 1:225-235.
26. Flkrig, E., S. W. Barthold, and R. A. Flavell. 1993. OspA vaccination of mice with established Borrelia burgdorferi infection alters disease but not infection. Infect. Immun. 61:2553-2557.
27. Gardiner, E. M., and P. Tattersall. 1988. Mapping of the fibrotropic and lymphotropic host range determinants of the parvovirus minute virus of mice. J. Virol. 62:2605-2613.
28. Ge, Y., S. Powell, M. Van Roey, and J. G. McArthur. 2001. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood 97:3733-3737.
29. Hernandez, Y. J., J. Wang, W. G. Kearns, S. Loiler, A. Poirier, and T. R. Flotte. 1999. Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J. Virol. 73:8549-8558.
30. High, K. 2002. adeno-associated virus-mediated gene transfer for hemophilia. Genet. Med. 4:56S-61S.
31. Kimsey, P. B., H. D. Engers, B. Hirt, and C. V. Jongeneel. 1986. Pathogenicity of fibroblast- and lymphocyte-specific variants of minute virus of mice. J. Virol. 59:8-13.
32. Leo, O., M. Foo, D. H. Sachs, L. E. Samelson, and J. A. Bluestone. 1987. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. 84:1374-1378.
33. Levin, D., S. Constant, T. Pasqualini, R. Flavell, and K. Bottomly. 1993. Role of dendritic cells in the priming of CD4+ T lymphocytes to peptide antigen in vivo. J. Immunol. 151:6742-6750.
34. Liu, D. W., Y. P. Tsao, J. T. Kung, Y. A. Ding, H. K. Sytwu, X. Xiao, and S. L. Chen. 2000. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J. Virol. 74:2888-2894.
35. Liu, Y., M. Chiriva-Internati, F. Grizzi, E. Salati, J. J. Roman, S. Lim, and P. L. Hermonat. 2001. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Ther. 8:948-957.
36. + T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immun. 69:681-686.
37. Monahan, P. E., and R. J. Samulski. 2000. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol. Med. Today 6:433-440.
38. Newman, M. J. 2002. Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses. Curr. Opin. Investig. Drugs 3:374-378.
39. Nicklin, S. A., and A. H. Baker. 2002. Tropism-modified adenoviral and adeno-associated virus vectors for gene therapy. Curr. Gene Ther. 2:273-293.
40. Palmer, G. A., and P. Tattersall. 2000. Autonomous parvoviruses as gene transfer vectors, p. 178-200. In S. Faisst and J. Rommelaere (ed.), Contributions to microbiology, vol. 4: parvoviruses. Karger Press, Basel, Switzerland.
41. Pancholi, P., D. H. Lee, Q. Liu, C. Tackney, P. Taylor, M. Perkus, L Andrus, B. Brotman, and A. M. Prince. 2001. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 33:448-454.
42. Paul, P. S., W. L. Mengeling, and T. T. Brown, Jr. 1979. Replication of porcine parvovirus in peripheral blood lymphocytes, monocytes, and peritoneal macrophages. Infect. Immun. 25:1003-1007.
43. Ponnazhagan, S., G. Mahendra, D. T. Curiel, and D. R. Shaw. 2001. Adenoassociated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. J. Virol. 75:9493-9501.
44. Ramshaw, I. A., and A. J. Ramsay. 2000. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 21:163-165.
45. Rommelaere, J., and P. Tattersall. 1990. Oncosuppression by parvoviruses, p. 41-58. In P. Tjissen (ed.), Handbook of parvoviruses, vol. II. CRC Press, Boca Raton, Fla.
46. Russell, S. J., A. Brandenburger, C. L. Flemming, M. K. Collins, and J. Rommelaere. 1992. Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus. J. Virol. 66:2821-2828.
47. Samelson, L. E., J. J. O'Shea, H. Luong, P. Ross, K. B. Urdahl, R. D. Klausner, and J. Bluestone. 1987. T-cell antigen receptor phosphorylation induced by an anti-receptor antibody. J. Immunol. 139:2708-2714.
48. Sarukhan, A., S. Camugli, B. Gjata, H. von Boehmer, O. Danos, and K. Jooss. 2001. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant virus vectors. J. Virol. 75:269-277.
49. Schneider, H., C. Muhle, A. M. Douar, S. Waddington, Q. J. Jiang, K. von der Mark, C. Coutelle, and W. Rascher. 2002. Sustained delivery of therapeutic concentrations of human clotting factor IX-a comparison of adenoviral and adeno-associated virus vectors administered in utero. J. Gene Med. 4:46-53.
50. Segovia, J. C., J. A. Bueren, and J. M. Almendral. 1995. Myeloid depression follows infection of susceptible newborn mice with the parvovirus minute virus of mice (strain i). J. Virol. 69:3229-3232.
51. Snapper, C. M., and W. E. Paul. 1987. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236:944-947.
52. Stilwell, J. L., and R. J. Samulski. 2003. Adeno-associated virus vectors for therapeutic gene transfer. BioTechniques 50:152-154.
53. Tattersall, P. 1972. Replication of the parvovirus MVM. I. Dependence of virus multiplication and plaque formation on cell growth. J. Virol. 10:586-590.
54. Tattersall, P., and J. Bratton. 1983. Reciprocal productive and restrictive virus-cell interactions of immunosuppressive and prototype strains of minute virus of mice. J. Virol. 46:944-955.
55. Tattersall, P., and E. M. Gardiner. 1990. Autonomous parvovirus-host interactions, p. 111-122. In P. Tjissen (ed.), Handbook of parvoviruses, vol. I. CRC Press, Boca Raton, Fla.
56. Wright, J. F., G. Qu, C. Tang, and J. M. Sommer. 2003. Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. Curr. Opin. Drug Discov. Dev. 6:174-178.
57. Wrzesinski, C., L. Tesfay, N. Salome, J. C. Jauniaux, J. Rommelaere, J. Cornelis, and C. Dinsart. 2003. Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells. J. Virol. 77:3851-3858.
58. Xiao, W., N. Chirmule, M. A. Schnell, J. Tazelaar, J. V. Hughes, and J. M. Wilson. 2000. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol. Ther. 1:323-329.
59. Xin, K. Q., T. Ooki, H. Mizukami, K. Hamajima, K. Okudela, K. Hashimoto, Y. Kojima, N. Jounoi, Y. Kumamoto, S. Sasaki, D. Klinman, K. Ozawa, and K. Okuda. 2002. Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum. Gene Ther. 13:1571-1581.
60. Zaiss, A. K., Q. Liu, G. P. Bowen, N. C. Wong, J. S. Bartlett, and D. A. Muruve. 2002. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 76:4580-4590.